Eupraxia Pharmaceuticals (EPRX) Assets Average (2024 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Assets Average for 3 consecutive years, with $115.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average rose 260.73% year-over-year to $115.8 million; the TTM figure through Mar 2026 stood at $115.8 million (up 260.73% YoY), while the FY2025 annual figure was $60.5 million, up 119.34% from the prior year.
• Assets Average improved to $115.8 million in Q1 2026 per EPRX's latest filing, from $89.2 million in the prior quarter.
• Across five years, Assets Average topped out at $115.8 million in Q1 2026 and bottomed at $17.7 million in Q3 2024.
• Historically, Assets Average has averaged $46.8 million across 3 years, with a median of $30.8 million in 2024.
• On a YoY basis, Assets Average climbed as much as 293.97% in 2025 and fell as far as 14.25% in 2025.
• Eupraxia Pharmaceuticals' Assets Average stood at $22.7 million in 2024, then soared by 293.97% to $89.2 million in 2025, then increased by 29.69% to $115.8 million in 2026.
• Business Quant data shows EPRX's Assets Average at $115.8 million in Q1 2026, $89.2 million in Q4 2025, and $58.0 million in Q3 2025.